ELV logo

Elevance Health

ELV · What the business does, what can go wrong, and how options sellers approach it

What it does

Elevance Health is a major US health insurer. It sells medical coverage to employers, individuals and government program enrollees. It is a licensee of Blue Cross Blue Shield branded plans, operating under those names in a number of states.

Beyond insurance, the company runs health services businesses, including pharmacy benefit management and care delivery operations.

How it makes money

Customers or government programs pay premiums, and Elevance pays for members' medical and pharmacy claims. The gap between premiums collected and claims paid, after administrative costs, is the core of its profit. Insurers also earn investment income on the premiums they hold before claims are paid.

Employers with their own self-funded plans pay fees for administration and network access instead of premiums. Its health services units earn fees and margins from pharmacy and care-related activity.

Why investors own it

Health coverage is a steady need, and the business can be relatively defensive through economic cycles. Scale gives it negotiating power with hospitals and drug suppliers. Its government-sponsored lines (Medicaid and Medicare Advantage) offer exposure to long-term demand from an aging population. The stock is also a common holding among investors seeking health care exposure and has historically paid a dividend, though dividends are never guaranteed.

What can go wrong

  • Medical costs can rise faster than premiums, squeezing margins.
  • Government programs depend on reimbursement rates and rules that can change.
  • Regulation, political scrutiny of insurers and pharmacy benefit managers, and policy shifts can affect profits.
  • Medicaid enrollment and eligibility changes can alter the mix and risk of its members.
  • Integration of acquisitions and growth in services businesses carries execution risk.

What to watch

  • Medical loss ratio (share of premiums spent on claims)
  • Medical cost trends and utilization
  • Membership by line of business
  • Government rate notices for Medicare Advantage and Medicaid
  • Regulatory and legislative developments
  • Guidance updates and commentary at quarterly results

Options income angle

Options on ELV are generally liquid, with a broad range of strikes and expirations, though trading is thinner in far-dated or far out-of-the-money contracts. Implied volatility tends to rise ahead of quarterly earnings, around government rate announcements, and when policy or medical cost concerns hit the managed care group.

One caution for premium sellers: this stock can gap sharply on earnings or sector news when cost trends surprise. A short option can lose far more than the premium collected in such a move, so position size and assignment risk deserve careful thought.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 6, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Elevance Health grew revenue sharply in 2025, but profit fell because medical costs rose faster than premiums, especially in its ACA individual-market (Public Exchange) business. Medicaid membership kept shrinking. The filing points to expired federal premium subsidies, expanded Medicare Advantage audits and new Medicaid rules as the main uncertainties ahead.

How the business did

  • Operating revenue was $197,584 million, up 12.8%, driven by premium rate increases, recent acquisitions and Medicare Advantage growth, partly offset by Medicaid membership attrition.
  • Shareholders' net income was $5,662 million, down 5.3%, and diluted EPS was $25.21, down 1.8%. The Health Benefits segment's operating gain fell to $4,158 million from $6,243 million, on higher medical cost trend. The benefit expense ratio (benefit costs as a share of premium revenue) rose to 90.0% from 88.5%.
  • CarelonRx operating revenue rose 20.7% and Carelon Services rose 57.7%. Both segments increased operating gain.
  • Operating cash flow was $4,290 million, down from $5,808 million, mainly because of a $666 million Blue Cross Blue Shield antitrust provider settlement paid in September 2025. The company spent $2,605 million on share repurchases and $1,529 million on dividends.
  • A lower effective tax rate of 15.6% (24.5% a year earlier) helped, due to a one-time tax benefit from an internal restructuring and favorable resolution of uncertain tax positions.

Risks specific to this company

  • ACA exchange costs: Enhanced premium tax credits (federal subsidies that lowered exchange premiums) expired on December 31, 2025. The filing says this may reduce individual-market enrollment, and that earlier enrollment shifts had already pushed up medical costs.
  • Medicare Advantage audits: In May 2025, CMS announced plans to substantially increase the scale and pace of RADV audits, which check the diagnosis data behind payments. Outcomes could lead to payment recoveries.
  • Medicaid exposure: Medicaid membership fell to 8,500 thousand from 8,917 thousand. The One Big Beautiful Bill Act adds more frequent eligibility checks and work requirements, with many provisions taking effect in 2027 and 2028.
  • Blue Cross license: The company depends on its BCBSA licenses. If they were terminated, the BCBSA could impose a "Re-establishment Fee" of $98.33 per enrollee, which the filing says would be approximately $3 billion on its roughly 34 million Blue enrollees.
  • Pharmacy dependence and reform: CarelonRx delegates core pharmacy benefit services to CVS under an agreement running through December 31, 2027. The Consolidated Appropriations Act adds rebate pass-through and reporting rules for pharmacy benefit managers.
  • Balance sheet: Goodwill and other intangibles were approximately $39.5 billion, or 32.5% of total assets, so impairment is possible. The parent company also relies on dividends from regulated subsidiaries, which state law limits.

What management is watching

  • Medical cost trend. Management says it is working with states, strengthening care management and refining its clinical strategy to lower Medicaid and exchange costs.
  • Medicare Star Ratings. About 59% of Medicare Advantage members are in plans rated at least 4.0 stars in the 2026 ratings, versus about 40% in 2025. The 2026 ratings set quality bonus payments in 2027.
  • Regulation: OBBBA implementation, the marketplace rule litigation, mental health parity rules and pharmacy benefit manager reform.
  • Capital: about $2,100 million of subsidiary dividends expected in 2026, $6,695 million of remaining share repurchase authorization, and a debt-to-capital ratio of 42.1%.
  • Measures management uses: operating gain and operating margin for segment performance, and the benefit expense ratio.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 21, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Elevance Health's third-quarter profit rose, but profit for the first nine months of the year fell. Shareholders' net income was $1,365 million for the quarter, up 14.8%, helped by investment income. For the nine months it was $4,592 million, down 10.2%, mainly because of a loss contingency accrual (money set aside for a probable cost) tied to Medicare Advantage risk adjustment data, plus weaker Health Benefits results.

How the business did

  • Revenue: Operating revenue was $50,440 million for the quarter, up 0.7%, and $149,760 million for the nine months, up 1.0%. Premium rate increases and CarelonRx growth were partly offset by lower Medicare Advantage, Medicaid and Employer Group Risk-Based membership. Total medical membership fell 1.1% year over year, and Medicare Advantage membership fell 15.5%.
  • Profit: Diluted earnings per share were $6.27 for the quarter versus $5.32 a year earlier, and $21.01 for the nine months versus $22.67. Net investment income was $1,037 million versus $625 million in the quarter, and amortization of intangible assets was lower. A higher tax bill partly offset these gains.
  • Segments: Health Benefits operating gain was $436 million versus $601 million for the quarter, on higher medical costs and technology spending. CarelonRx rose to $616 million from $556 million on better specialty pharmacy profitability. Carelon Services rose to $292 million from $219 million. The benefit expense ratio (medical costs as a share of premiums) was 90.6% versus 91.3% for the quarter, helped by Medicare. For the nine months it was 89.0% versus 88.9%, with Medicaid costs elevated.
  • Cash and capital: Operating cash flow for the nine months was $7,512 million versus $4,206 million, mostly from favorable working capital. The company spent $1,688 million on share repurchases and $1,122 million on dividends. It also made net debt repayments of $900 million. Debt-to-capital was 40.7% versus 42.1% at December 31, 2025.
  • Unusual item: On July 13, 2026, CMS told the company it had completed all required steps on the risk adjustment data matter, that no sanctions would be imposed, and that the enforcement process was closed.

What management is watching

  • Cost trends: Medicaid costs remain elevated because members are sicker and use more services. In the individual ACA market, enhanced subsidies expired on December 31, 2025, and members who stayed in the market have driven up medical costs. Management expects its cost initiatives to build over time.
  • Spending: The 2026 - 2027 Operating Model Transformation Program covers technology modernization, artificial intelligence, and targeted workforce reductions. It was still under way at September 30, 2026. Technology investment also raised operating expenses.
  • Quality ratings and partners: About 49% of Medicare Advantage members are in plans rated 4.0 Stars or higher under the 2027 ratings, versus about 55% under the 2026 ratings. Plans need 4.0 Stars to earn bonus payments. CarelonRx signed a new five-year agreement with CVS running January 1, 2027 through December 31, 2031.
  • Measures: Management points to operating gain, operating margin and the debt-to-capital ratio, and says the nine-month results are not necessarily indicative of the full year.

Follow ELV in Kortex

The Kortex app shows ELV's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.